Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic mCRPC
NCT01591122Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2012
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Started Mar 2012; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01591122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01591122.